CCAL
LGND icon

City Center Advisors LLC’s Ligand Pharmaceuticals LGND Stock Holding History

City Center Advisors LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,266
Closed -$400K – 197
2026
Q2 		$400K Sell
1,266
-529
-29% -$125K 0.32% 98
2026
Q1 		$358K Buy
+1,795
New +$355K 0.33% 95

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

City Center Advisors LLC's LGND Position: Q3 2026 in Review

City Center Advisors LLC sold out of Ligand Pharmaceuticals (LGND) in Q3 2026, closing a stake of 1,266 shares — an estimated $400K sold.

City Center Advisors LLC first reported a position in LGND in Q1 2026 and held it in 2 quarters. The position peaked at $400K in Q2 2026. 14 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • City Center Advisors LLC reported no remaining Ligand Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • City Center Advisors LLC sold 1,266 Ligand Pharmaceuticals shares in Q3 2026, an estimated $400K.
  • City Center Advisors LLC first reported a position in Ligand Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • City Center Advisors LLC's Ligand Pharmaceuticals position peaked at $400K in Q2 2026.
  • 14 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on City Center Advisors LLC's 13F filing for Q3 2026, filed 8 Oct 2026.